Preclinical mouse models for studying cholangiocarcinoma
10.1016/j.livres.2026.01.002
- Author:
Shanru Yang
;
Chaodi Bao
;
Yuan Li
;
Yangxiang Ou
;
Yifan Jiang
;
Wenjie Xu
;
Dongfang Zheng
;
Na Li
;
Mengjie Yang
;
Fuyan Wang
;
Xin Hou
- Publication Type:Review
- From:
Liver Research
2026;10(1):22-34
- CountryChina
- Language:English
-
Abstract:
Cholangiocarcinoma (CCA) is a malignancy characterized by tumor cells originating in the liver or bile ducts, exhibiting features of cholangiocyte differentiation. It poses a significant clinical challenge due to the limited diagnostic and therapeutic options available. Robust animal models are essential for advancing our understanding of CCA pathogenesis and developing effective treatments. This review provides a comprehensive overview of CCA mouse models, highlighting various approaches, including chemical induction, genetically engineered models, and tumor xenografts. Each model is discussed in terms of its establishment techniques, pathological characteristics, and research significance, with a focus on intrahepatic CCA. Chemical induction models, such as diethylnitrosamine- and azoxymethane-induced models, offer insights into tumorigenesis processes, whereas genetically modified models involving alterations in key genes such as Kirsten rat sarcoma viral oncogene homolog, tumor protein 53, and isocitrate dehydrogenase serve as important tools for studying the molecular mechanisms underlying CCA. Xenograft models, including patient-derived xenografts, bridge the gap between experimental research and clinical applications, allowing for precise therapeutic evaluations. By comparing these models, this review underscores their respective advantages and limitations, paving the way for future studies aiming to optimize and innovate CCA modeling strategies.
